COMT inhibitors, meant to boost Parkinson’s treatment, unintentionally promote gut bacteria that break down levodopa. This microbiome-mediated interaction hinders the drug's effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results